Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations

Summary

During surgery and childbirth, patients with hereditary antithrombin (AT) deficiency are at high risk for thrombosis,and heparin prophylaxis may not be sufficiently efficacious. In these patients, exogenous AT may be used in association with heparin. A recombinant human AT (generic name: antithrombin alfa) has been developed. This multi-center study assessed the efficacy and safety of prophylactic intravenous administration of antithrombin alfa to hereditaryAT deficient patients in high risk situations, including elective surgery, childbirth, or cesarean section. Antithrombin alfa was administered prior to and during the high risk period for restoration and maintenance of AT activity at 100% of normal. Heparin, low-molecular-weight heparin, and/or vitamin K antagonists were used according to standard of care. The primary efficacy endpoint was the incidence of acute deep vein thrombosis (DVT) from baseline up to day 30 post dosing as assessed by independent central review of duplex ultrasonograms and/or venograms. Safety was assessed based on adverse events (AEs) and laboratory evaluations. Five surgical and nine obstetrical hereditary AT deficiency patients received antithrombin alfa for a mean period of seven days.No clinically overt DVT occurred. Central review of ultrasonograms identified signs of acute DVT in two out of 13 evaluable patients. No antithrombin alfa-related AEs were reported. No patient developed anti-antithrombin alfa antibodies. In conclusion, this study suggests that antithrombin alfa is a safe and effective alternative to human plasma-derived AT for treating hereditary AT deficiency patients at high risk for thromboembolic events.

Keywords

Hereditary antithrombin deficiency - recombinant human antithrombin - antithrombin alfa - ATryn^ - deep vein thrombosis

• References

• 1 Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995; 74: 94-100.
• 2 Pabinger I, Vormittag R. Thrombophilia and pregnancy outcomes. J Thromb Haemost 2005; 3: 1603-1610.
• 3 Büller HR, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.
• 4 Bucur SZ, Levy JH, Despotis GJ. et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998; 38: 481-498.
• 5 Edmunds T, Van Patten SM, Pollock J. et al. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91: 4561-4571.
• 6 Antithrombin alfa (Atryn) Investigator’s Brochure.
• 7 Konkle BA, Bauer KA, Weinstein R. et al. Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. Transfusion 2003; 43: 390-394.
• 8 Knight R, Stanley S, Wong M. et al. Hemophilia therapy and blood-borne pathogen risk. Semin Thromb Hemost 2006; 32 (Suppl. 02) 3-9.
• 9 Turner ML. Prion reduction filters. Lancet 2006; 368: 2190-2191.
• 10 Final Study Report: A single-dose pharmacokinetic study of recombinant human antithrombin (rhAT) III in patients with hereditary AT III deficiency. Data on file. GTC Biotherapeutics, Inc.; MA, USA: 2003
• 11 Menache D. Replacement therapy in patients with hereditary antithrombin III deficiency. Semin Hematol 1991; 28: 31-38.
• 12 Brandt P. Observations during the treatment of antithrombin- III deficient women with heparin and antithrombin concentrate during pregnancy, parturition, and abortion. Thromb Res 1981; 22: 15-24.
• 13 Menache D, O’Malley JP, Schorr JB. et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 1990; 75: 33-39.
• 14 Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982; 14: 127-141.
• 15 Brandt P, Stenbjerg S. Subcutaneous heparin for thrombosis in pregnant women with hereditary antithrombin deficiency. Lancet 1979; 1: 100-101.
• 16 Elias A, Cadene A, Elias M. et al. Extended lower limb venous ultrasound for the diagnosis of proximal and distal vein thrombosis in asymptomatic patients after total hip replacement. Eur J Vasc Endovasc Surg 2004; 27: 438-444.
• 17 Robertson L, Greer I. Thromboembolism in pregnancy. Curr Opin Obstet Gynecol 2005; 17: 113-116.
• 18 Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16: 742-748.
• 19 McColl MD, Ramsay JE, Tait RC. et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 1183-1188.